Know Cancer

or
forgot password

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler


N/A
18 Years
N/A
Not Enrolling
Both
Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Refractory Anemia With Excess of Blasts (RAEB)

Thank you

Trial Information

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler


Inclusion Criteria:



1. Subjects with a cytopathologically confirmed diagnosis of AML subjects with
refractory anemia with excess of blasts (RAEB) according to the WHO 2008
classification

2. ≥ 18 years

3. Written informed consent

Exclusion Criteria:

1. Subjects without a cytopathologically confirmed diagnosis of AML subjects with
refractory anemia with excess of blasts (RAEB) according to the WHO 2008
classification

2. < 18 years

3. Without written informed consent

Type of Study:

Observational

Study Design:

Observational Model: Case-Only

Outcome Measure:

Acceptance Criteria

Outcome Description:

The acceptance criteria based on lower level of the 95% CI of the positive or negative percent agreement for all markers.

Outcome Time Frame:

Sample taken at initial visit with no follow up (Day 1)

Safety Issue:

No

Principal Investigator

Martin Tallman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

PROT-015

NCT ID:

NCT01463410

Start Date:

October 2011

Completion Date:

March 2013

Related Keywords:

  • Acute Myeloid Leukemia (AML)
  • Acute Promyelocytic Leukemia (APL)
  • Refractory Anemia With Excess of Blasts (RAEB)
  • Anemia
  • Anemia, Refractory
  • Anemia, Refractory, with Excess of Blasts
  • Chromosome Aberrations
  • Chromosome Disorders
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Promyelocytic, Acute

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021
James Cancer HospitalColumbus, Ohio  43210